Bedside

A Luxurious Retreat for Body, Mind, and Soul at Acqualina Resort

Retrieved on: 
Wednesday, January 31, 2024
Yoga, Technogym, Stress, Create, Creativity, Weight loss, Sony, Meditation, Resort, Exercise, Pilates, Zumba, Bedside, Music therapy, Water, Map, USA Today, Massage, Collection, Forbes Travel Guide, Relaxation, CBD, Outdoor, Mental health, Inflammation, Human, Mindfulness, Art therapy, Five star, Rejuvenation, Concierge, Health, Woman

WESTON, Fla., Jan. 31, 2024 /PRNewswire-PRWeb/ -- AcquaFit is the premier health and fitness program at Acqualina Resort & Residences offering a holistic approach to wellness. It's a complete well-being journey that fosters physical, mental and emotional health. Whether you're interested in fitness classes, mindfulness programs or simply looking to unwind in style, AcquaFit offers a range of options to help you achieve your wellness goals during your Miami stay.

Key Points: 
  • Acqualina Resort is thrilled to introduce AcquaFit, a comprehensive wellness program crafted to uplift every aspect of your being.
  • WESTON, Fla., Jan. 31, 2024 /PRNewswire-PRWeb/ -- AcquaFit is the premier health and fitness program at Acqualina Resort & Residences offering a holistic approach to wellness.
  • Whether practiced in-room or at designated meditation spots around the resort, these sessions promote a sense of calm and tranquility.
  • It features luxurious treatment rooms, relaxation lounges, a Royal Spa Suite for special occasions, and a magnificent outdoor terrace retreat.

Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

Retrieved on: 
Tuesday, January 2, 2024
FDA, Patient, Food, Bedside, Blood

Oak Ridge, TN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024. The Company’s mission is to advance healthcare by enabling optimal fluid management.

Key Points: 
  • The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside
    Oak Ridge, TN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway.
  • Potential clearance is expected during the first half of 2024.
  • The new Daxor BVA device directly quantifies the intravascular blood, red blood cell and plasma volume, providing clinicians with actionable information to achieve optimal fluid management for their patients.
  • “Funded under contract by the U.S. Department of Defense, our next-generation analyzer will deliver a level of speed, access, and accuracy to blood volume management that can significantly improve care and outcomes in medicine.”

MatriSys Bioscience Co-Founder Richard Gallo, MD, PhD Honored by AAD and AAAAI

Retrieved on: 
Monday, March 20, 2023
Eugene, Piper LBP, American Academy of Dermatology, Skin, BOCA, Atopic dermatitis, American Academy, Research, AAD, AAAAI, Innovation, Health, New Orleans, Pharmaceutical industry, Medical device, Bedside

BOCA RATON, Fla., March 20, 2023 /PRNewswire/ -- MatriSys BioScience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic dermatologic indications, today announced that its scientific co-founder, Dr. Richard Gallo, received the Eugene J Van Scott award for Innovative Therapy of the Skin from the American Academy of Dermatology (AAD).

Key Points: 
  • BOCA RATON, Fla., March 20, 2023 /PRNewswire/ -- MatriSys BioScience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic dermatologic indications, today announced that its scientific co-founder, Dr. Richard Gallo, received the Eugene J Van Scott award for Innovative Therapy of the Skin from the American Academy of Dermatology (AAD).
  • This award was created in 2007 to recognize innovation in the treatment of skin diseases and conditions.
  • Dr. Gallo will be presenting the Philip Frost Leadership lecture during the AAD conference plenary session in New Orleans LA on March 19.
  • The application of Dr. Gallo's research into the microbiome of the skin provides new opportunities to advance patient care in atopic dermatitis and other chronic conditions.

ASTCT to Present Distinguished Honors at the 2023 Tandem Meetings

Retrieved on: 
Tuesday, January 17, 2023
Pharmacist, National Cancer Institute, Bedside, Blood, NCI, ASCO, Lymphoma, Lymphatic system, Degenerative disease, Fred Hutchinson Cancer Research Center, Haematopoietic system, Nursing, FDA, Knowledge, Immune tolerance, ASH, Lecture, AACR, Tandem, Patient, Transplant, Society, GVHD, Doctor of Philosophy, Physician, Leukemia, Dentistry, MD, Bench

CHICAGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- American Society for Transplantation and Cellular Therapy (ASTCT) will present top awards to leaders in the field of transplantation and cellular therapy at the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® on Saturday, Feb. 18 in Orlando, Florida.

Key Points: 
  • CHICAGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- American Society for Transplantation and Cellular Therapy (ASTCT) will present top awards to leaders in the field of transplantation and cellular therapy at the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® on Saturday, Feb. 18 in Orlando, Florida.
  • Fred Appelbaum, MD will receive the 2023 ASTCT Lifetime Achievement Award.
  • Additional information about the 2023 award winners is available on the 2023 Tandem Meetings website .
  • Follow #Tandem23 for the latest updates on the 2023 Tandem Meetings.

Publix Pharmacy now offering bedside delivery at Manatee Memorial Hospital

Retrieved on: 
Thursday, December 15, 2022
Retail, Health, Hospitals, Supermarket, Pharmaceutical, Food, Beverage, Bariatric surgery, Publix, Patient, General surgery, Cancer, Insurance, Stroke, Heart, Palmetto, Hope, Bedside, Manatee Memorial Hospital, Pharmacy, Healthcare, Hospital

Publix Pharmacy and Manatee Memorial Hospital, located in Bradenton, Florida, are teaming up to provide bedside delivery of prescription medications to patients before theyre discharged.

Key Points: 
  • Publix Pharmacy and Manatee Memorial Hospital, located in Bradenton, Florida, are teaming up to provide bedside delivery of prescription medications to patients before theyre discharged.
  • We are excited to extend bedside delivery of prescription medications to patients of Manatee Memorial Hospital and hope to help with their road to recovery after discharge.
  • Our goal in our collaboration with Publix Pharmacy is to provide our patients with the medications they need to keep them healthy before they leave the building, said Manatee Memorial Hospital Director of Pharmacy James Wengerd.
  • Manatee Memorial Hospital, a member of the Manatee Healthcare System, has served the residents of Manatee, Hillsborough and surrounding counties for over 69 years.

THE VAST MAJORITY OF AMERICANS DISTRUST THE HEALTHCARE SYSTEM BELIEVING THE FOCUS IS ON PROFITS OVER PEOPLE

Retrieved on: 
Monday, November 21, 2022
Family, Friends, Organization, Bedside, Safety, NPHI, Health care, Patient, Hospice, Life, National Partnership, Medicine

WASHINGTON, Nov. 21, 2022 /PRNewswire/ -- New data from a National Partnership for Healthcare and Hospice Innovation (NPHI ) nationwide survey shows that 82% of Americans believe the U.S. healthcare system puts profits ahead of people, and 72% believe healthcare groups are not doing a good job caring for folks as they age.

Key Points: 
  • The survey data reinforces the critical role that our member organizations provide in the communities they serve.
  • They are guided by empathic and compassionate individuals who make critical decisions at the bedside and not the boardroom."
  • MILLIONS IN CHARITY CARE: Every year NPHI members care for over 400,000 patients and their families.
  • Since late in life care is provided without regard for profit, NPHI members can help ease these concerns.

Concord Medical Announces the Successful Holding of the Second Annual Academic Meeting with the world well-known MD Anderson

Retrieved on: 
Wednesday, November 16, 2022
Monroe Dunaway Anderson, Anderson, Fudan University, Forward-looking statement, Meeting, University, Company, Nursing management, Education, NYSE, CCM, Research, Phrase, The Meeting, Patient, Radiation, Renji Hospital, Hospital, Shanghai Cancer Center, Oncology, MD Anderson Cancer Center, Method, Ruijin Hospital, Cancer, Pharmaceutical industry, Medical device, Medical imaging, Immunotherapy, Bedside

12 experts from MD Anderson participated in the Meeting, including nine of which as guest speakers and three as moderators and opening speakers.

Key Points: 
  • 12 experts from MD Anderson participated in the Meeting, including nine of which as guest speakers and three as moderators and opening speakers.
  • Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "I would like to express my heartfelt thanks to the experts who spoke on and participated in the Meeting.
  • MD Anderson is one of the best-known cancer treatment centers globally and the largest cancer center in the United States.
  • Leveraging years of strategic cooperation, MD Anderson and Shanghai Concord Cancer Center successfully cohosted the First Annual Academic Meeting in November 2021.

Genixus™ Introduces Propofol as the First Product to be Delivered Within KinetiX™ Ready-to-Administer (RTA) Syringe Platform

Retrieved on: 
Tuesday, August 9, 2022
Workflow, OR, Conference, RTA, Kinetix, Bedside, Medicine, Propofol

LAS VEGAS, Aug. 9, 2022 /PRNewswire/ -- Genixus™, a pharmaceutical company focused on transforming acute and critical care medicines, today announced that it will offer Propofol as the first product within its KinetiX™ platform of RTA syringe products at the Annual National Pharmacy Purchasing Association Conference (booth # 603-605). 

Key Points: 
  • "Following the recent 503B registration and licensing of our facility in North Carolina, Genixus is excited to deliver an RTA format of Propofol, one of the most commonly used medications within the OR setting" said Seth Coombs , Co-Founder & Chief Commercial Officer of Genixus.
  • "Our KinetiX platform is designed to deliver clinical tools that seamlessly integrate intothe operations of the acute and critical care setting, allowing clinicians to focus on their ultimate goal: the quality of care and patient outcomes."
  • The new Propofol Syringe is the first product to be available within the KinetiX RTA platform, which is designed to simplify workflow and support effective care delivery.
  • To support error resistance and clinical efficiency, KinetiX Propofol features several key attributes:

INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer

Retrieved on: 
Thursday, June 16, 2022
HERE, Security (finance), MUC4, Science, Trastuzumab, Survival, TNF, Disease, Marketing, Inflammation, Neoplasm, Toxicity, GLOBE, ADC, Lapatinib, CEO, Private Securities Litigation Reform Act, NASDAQ, Tyrosine, Natural killer cell, FDA, HER2, MDSC, TME, Biomarker, Patient, TILS, U.S. Securities and Exchange Commission, TAM, Blood, Woman, Breast cancer, Risk, US Foods, NK, Tucatinib, Tumor microenvironment, Company, Cancer, Instituto de Biología y Medicina Experimental, Research, Data, Food, Medical imaging, Pharmaceutical industry, Vaccine, BC, Bedside, Immunotherapy

Boca Raton, Florida, June 16, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has been invited to present data on reversing resistance to HER2 targeted immunotherapy at the HER2 Targeted Therapy Summit in Boston.  

Key Points: 
  • In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab based therapies, and promotes an immunologically active TME.
  • Data presented at noon today at the HER2 Targeted Therapy Summit in Boston.
  • The presentation will present both the science driving MUC4-based resistance mechanisms and the translation of these pre-clinical studies to the clinic.
  • We have identified three reversable resistance mechanisms in women with HER2+/MUC+ breast cancer resistance to trastuzumab, resistance to tyrosine kinaseinhibitors(eg: lapatinib and tucatinib) and a cold immunosuppressive TME.

Acqualina Resort Debuts An Exquisitely Decadent New Adult Pool Experience

Retrieved on: 
Friday, June 3, 2022
Diamond, Paspalum, Atlantic Ocean, Table, Privacy, Adult, Tea, Ebook, Partner, Residence, Wine, CEO, Relaxation, American Automobile Association, Bed, Ice, Amalfi Coast, Water, Television, Bedside, Hotel

MIAMI, June 3, 2022 /PRNewswire-PRWeb/ -- The ultra-luxurious Acqualina Resort & Residences in Miami's Sunny Isles Beach introduces an elevated pool experience at the Adult Pool nestled on the property's north side, surrounded by palm trees and greenery. This oceanfront tranquility haven for guests 18 years and over has become more sublime with curated menu offerings, personalized service, and refreshed interiors designed in the resort's signature red hues. The new adult pool experience features four expansive cabanas, modern chaise lounges with side tables, love seats, wide umbrellas, and eight custom day beds in rich red tones.

Key Points: 
  • MIAMI, June 3, 2022 /PRNewswire-PRWeb/ -- The ultra-luxurious Acqualina Resort & Residences in Miami's Sunny Isles Beach introduces an elevated pool experience at the Adult Pool nestled on the property's north side, surrounded by palm trees and greenery.
  • The new adult pool experience features four expansive cabanas, modern chaise lounges with side tables, love seats, wide umbrellas, and eight custom day beds in rich red tones.
  • "The new adult pool experience encourages leisurely days and luxury lounging in exquisite surroundings."
  • In addition, courtesy of long-time Acqualina bartender Franco Amendola, who hails from the Amalfi Coast, comes a specialty cocktail, the Acqualina Spritz, created exclusively for the adult pool experience.